Opportunities and challenges for anti-CD73 cancer therapy

Immunotherapy

Volumn 4, Issue 9, 2012, Pages 861-865

  Zhang, Bin ^a,b,c  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b University of Texas Health Science Center at San Antonio   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

adenosine; CD73; ecto 5 nucleotidase; immunosuppression; microenvironment; tumor

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE A2 RECEPTOR; ADENOSINE PHOSPHATE; CD39 ANTIGEN; DEATH RECEPTOR 5; GAMMA INTERFERON; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; SMALL INTERFERING RNA; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CHEMOTAXIS; DENDRITIC CELL; ENDOTHELIUM; ENZYME ACTIVITY; HUMAN; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT;

5'-NUCLEOTIDASE; ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84867351931     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.83     Document Type: Review

References (54)

1. Ohta A, Gorelik E, Prasad SJ et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci. USA 103, 13132-13137 (2006). (Pubitemid 44338928)
2. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 57, 2602-2605 (1997). (Pubitemid 27283766)
3. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol. Rev. 161, 95-109 (1998).
4. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signal. 2, 351-360 (2006).
5. Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res. 70, 6407-6411 (2010).
6. Deaglio S, Robson SC. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv. Pharmacol. 61, 301-332 (2011).
7. Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 33, 231-237 (2012).
8. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (review). Int. J. Oncol. 32, 527-535 (2008). (Pubitemid 351330458)
9. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29, 5346-5358 (2010).
10. Spychala J. Tumor-promoting functions of adenosine. Pharmacol. Ther. 87, 161-173 (2000).
11. Jin D, Fan J, Wang L et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 70, 2245-2255 (2010).
12. Stagg J, Divisekera U, McLaughlin N et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl Acad. Sci. USA 107, 1547-1552 (2010).
13. Hausler SF, Montalban Del Barrio I, Strohschein J et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol. Immunother. 60(10), 1405-1418 (2011).
14. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J. Immunol. 187, 676-683 (2011).
15. Stagg J, Divisekera U, Duret H et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 71, 2892-2900 (2011).
16. Yegutkin GG, Marttila-Ichihara F, Karikoski M et al. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur. J. Immunol. 41, 1231-1241 (2011).
17. Wang L, Fan J, Thompson LF et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J. Clin. Invest. 121, 2371-2382 (2011).
18. Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007). (Pubitemid 46919862)
19. Stagg J, Beavis PA, Divisekera U et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 72, 2190-2196 (2012).
20. Kryczek I, Banerjee M, Cheng P et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114, 1141-1149 (2009).
21. Chalmin F, Mignot G, Bruchard M et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 36, 362-373 (2012).
22. Ryzhov S, Novitskiy SV, Goldstein AE et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J. Immunol. 187, 6120-6129 (2011).
23. Sattler C, Steinsdoerfer M, Offers M et al. Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. Cell Transplant. 20, 1221-1230 (2011).
24. Saldanha-Araujo F, Ferreira FI, Palma PV et al. Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell Res. 7, 66-74 (2011).
25. Thomson LF, Ruedi JM, Glass A et al. Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5′-nucleotidase (CD73). Tissue Antigens 35, 9-19 (1990). (Pubitemid 20044689)
26. Yamashita Y, Hooker SW, Jiang H et al. CD73 expression and fyn-dependent signaling on murine lymphocytes. Eur. J. Immunol. 28, 2981-2990 (1998). (Pubitemid 28470244)
27. Airas L, Jalkanen S. CD73 mediates adhesion of B cells to follicular dendritic cells. Blood 88, 1755-1764 (1996). (Pubitemid 26307072)
28. Sadej R, Spychala J, Skladanowski AC. Ecto-5′-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells. Nucleosides Nucleotides Nucleic Acids 25, 1119-1123 (2006). (Pubitemid 44651858)
29. Sadej R, Inai K, Rajfur Z et al. Tenascin C interacts with ecto-5′-nucleotidase (eN) and regulates adenosine generation in cancer cells. Biochim. Biophys. Acta 1782, 35-40 (2008).
30. Wang L, Zhou X, Zhou T et al. Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J. Cancer Res. Clin. Oncol. 134, 365-372 (2008). (Pubitemid 351170058)
31. Mikhailov A, Sokolovskaya A, Yegutkin GG et al. CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis. J. Immunol. 181, 464-475 (2008).
32. Airas L, Niemela J, Jalkanen S. CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism. J. Immunol. 165, 5411-5417 (2000).
33. Airas L, Niemela J, Salmi M, Puurunen T, Smith DJ, Jalkanen S. Differential regulation and function of CD73, a glycosyl-phosphatidylinositol- linked 70 kD adhesion molecule, on lymphocytes and endothelial cells. J. Cell Biol. 136, 421-431 (1997). (Pubitemid 27063091)
34. Dianzani U, Redoglia V, Bragardo M et al. Co-stimulatory signal delivered by CD73 molecule to human CD45RAhiCD45ROlo (naive) CD8+ T lymphocytes. J. Immunol. 151, 3961-3970 (1993). (Pubitemid 23298729)
35. Whiteside TL. Disarming suppressor cells to improve immunotherapy. Cancer Immunol. Immunother. 61, 283-288 (2012).
36. Schreiber K, Rowley DA, Riethmuller G, Schreiber H. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol. Oncol. Clin. North Am. 20, 567-584 (2006). (Pubitemid 43817442)
37. Skipper HE. Cancer chemotherapy is many things: G.H.A. Clowes Memorial Lecture. Cancer Res. 31, 1173-1180 (1971).
38. Wen FT, Thisted RA, Rowley DA, Schreiber H. A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology 1, 172-178 (2012).
39. Aymeric L, Apetoh L, Ghiringhelli F et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 70, 855-858 (2010).
40. Sheth S, Bleibel W, Thukral C et al. Heightened NTPDase-1/CD39 expression and angiogenesis in radiation proctitis. Purinergic Signal. 5, 321-326 (2009).
41. Tsukimoto M, Homma T, Ohshima Y, Kojima S. Involvement of purinergic signaling in cellular response to gamma radiation. Radiat. Res. 173, 298-309 (2010).
42. Serra S, Horenstein AL, Vaisitti T et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118, 6141-6152 (2011).
43. Wieten E, van der Linden-Schrever BE, Sonneveld E, Veerman AJ, Pieters R. CD73 (5′-nucleotidase) expression has no prognostic value in children with acute lymphoblastic leukemia. Leukemia 25, 1374-1376 (2011).
44. Wu XR, He XS, Chen YF et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J. Surg. Oncol. 106(2), 130-137 (2012).
45. Supernat A, Markiewicz A, Welnicka-Jaskiewicz M et al. CD73 expression as a potential marker of good prognosis in breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 20, 103-107 (2012).
46. Thompson LF, Eltzschig HK, Ibla JC et al. Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med. 200, 1395-1405 (2004). (Pubitemid 39657287)
47. Niemela J, Henttinen T, Yegutkin GG et al. IFN-alpha induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5′- nucleotidase) up-regulation. J. Immunol. 172, 1646-1653 (2004). (Pubitemid 38116812)
48. Salmi M, Jalkanen S. Homing-associated molecules CD73 and VAP-1 as targets to prevent harmful inflammations and cancer spread. FEBS Lett. 585, 1543-1550 (2011).
49. St Hilaire C, Ziegler SG, Markello TC et al. NT5E mutations and arterial calcifications. N. Engl. J. Med. 364, 432-442 (2011).
50. Tsukamoto H, Chernogorova P, Ayata K et al. Deficiency of CD73/ecto-5′-nucleotidase in mice enhances acute graft-versus-host disease. Blood 119, 4554-4564 (2012).
51. Kunzli BM, Bernlochner MI, Rath S et al. Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal. 7, 231-241 (2011).
52. Sun X, Wu Y, Gao W et al. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139, 1030-1040 (2010).
53. Ryzhov S, Novitskiy SV, Zaynagetdinov R et al. Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia 10, 987-995 (2008).
54. Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J. Immunol. 188, 198-205 (2012).